Understanding how a specific RNA molecule influences gene regulation in cancer
Official title: Determining the role of the long non-coding RNA HOTTIP in regulation of the HOXA gene cluster
Funded at University of Chicago · NIH-11071293 · Data updated 2026-11-12
This study is looking at how a specific RNA called HOTTIP helps control important genes that affect limb development and are linked to cancer, with the hope of finding new ways to treat cancer that could benefit patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | January 1, 2025 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 1F31GM157953-01 |
| Project ID | NIH-11071293 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals affected by cancers associated with disruptions in non-coding RNAs, particularly those related to the HOXA gene cluster.
✕Less likely to help
Patients with cancers not linked to non-coding RNA disruptions or those unrelated to the HOXA gene cluster may not benefit from this research.
What this research studies
This research investigates the role of a long non-coding RNA called HOTTIP in regulating the HOXA gene cluster, which is crucial for limb development and is associated with various cancers. By utilizing advanced molecular engineering techniques, the project aims to clarify how HOTTIP interacts with other proteins to control gene expression. This understanding could lead to new therapeutic strategies targeting non-coding RNAs in cancer treatment. Patients may benefit from insights gained about the mechanisms of cancer progression and potential new treatment options.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies targeting non-coding RNAs, improving treatment options for cancer patients.
How similar studies have gone: Other research has shown promising results in targeting non-coding RNAs for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Zelko, Michael — University of Chicago
- Study coordinator: Zelko, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.